| P50 | author | Kim Brosen | Q43114329 |
| | Troels K Bergmann | Q50263085 |
| P2093 | author name string | Magnus Ingelman-Sundberg | |
| | Jónrit Halling | |
| | Pál Weihe | |
| | Hege Edvardsen | |
| | Vessela N Kristensen | |
| | Sarah C Sim | |
| | Charlotte Brasch-Andersen | |
| | Rasmus S Pedersen | |
| | Maria S Petersen | |
| P2860 | cites work | Cytochrome P4502C9: an enzyme of major importance in human drug metabolism | Q24683497 |
| | A New Statistical Method for Haplotype Reconstruction from Population Data | Q27860495 |
| | Haploview: analysis and visualization of LD and haplotype maps | Q27860955 |
| | The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans | Q28254348 |
| | Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily | Q28271091 |
| | Biochemistry and molecular biology of the human CYP2C subfamily | Q28299258 |
| | Clinical relevance of genetic polymorphisms in the human CYP2C subfamily | Q28362533 |
| | Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation | Q29617997 |
| | CYP2C19*17 is associated with decreased breast cancer risk | Q33339982 |
| | Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects | Q34713638 |
| | Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms | Q35566353 |
| | Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance | Q36131028 |
| | Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population | Q36535932 |
| | Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers | Q36729190 |
| | Oxidation of endobiotics mediated by xenobiotic-metabolizing forms of human cytochrome | Q37548458 |
| | Genetic polymorphism of S-mephenytoin hydroxylation | Q38692055 |
| | Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. | Q40773486 |
| | A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants | Q42168063 |
| | Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole | Q43106360 |
| | Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement | Q43190644 |
| | Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms | Q44218965 |
| | Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism | Q45193945 |
| | Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects | Q46463147 |
| | Cytochrome P450 2C19 genetic polymorphisms in Ugandans | Q46496567 |
| | Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population | Q46605128 |
| | Cytochrome P4502C9 (CYP2C9) genotypes in a Nordic population in Denmark | Q47853178 |
| | Association studies of estrogen receptor polymorphisms in a Norwegian testicular cancer population. | Q49304286 |
| | Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. | Q50557593 |
| | Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. | Q51901597 |
| | Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10 | Q52990038 |
| | Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. | Q54501796 |
| | A single-nucleotide polymorphism tagging set for human drug metabolism and transport | Q57309672 |
| | CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking | Q58003104 |
| | Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls | Q72176950 |
| | Association of polymorphisms in the cytochrome P450 (CYP) 2C19 and 2C18 genes in Japanese epileptic patients | Q74340236 |
| P433 | issue | 12 | |
| P921 | main subject | linkage disequilibrium | Q2064311 |
| | disequilibrium | Q5282160 |
| P304 | page(s) | 1199-1205 | |
| P577 | publication date | 2010-07-28 | |
| P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
| P1476 | title | Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations | |
| P478 | volume | 66 | |